Abstract
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Current Pharmaceutical Biotechnology
Title:Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Volume: 16 Issue: 5
Author(s): Tessalia D.L. Saraiva, Katia Morais, Vanessa B. Pereira, Marcela de Azevedo, Clarissa S. Rocha, Camila C. Prosperi, Ana C. Gomes-Santos, Luis Bermudez-Humaran, Ana M.C. Faria, Herve M. Blottiere, Philippe Langella, Anderson Miyoshi, Alejandra de Moreno de LeBlanc, Jean G. LeBlanc and Vasco Azevedo
Affiliation:
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Abstract: Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Export Options
About this article
Cite this article as:
Saraiva D.L. Tessalia, Morais Katia, Pereira B. Vanessa, Azevedo de Marcela, Rocha S. Clarissa, Prosperi C. Camila, Gomes-Santos C. Ana, Bermudez-Humaran Luis, Faria M.C. Ana, Blottiere M. Herve, Langella Philippe, Miyoshi Anderson, LeBlanc de Moreno de Alejandra, LeBlanc G. Jean and Azevedo Vasco, Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model, Current Pharmaceutical Biotechnology 2015; 16 (5) . https://dx.doi.org/10.2174/1389201015666141113123502
DOI https://dx.doi.org/10.2174/1389201015666141113123502 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Nanoparticles for Colorectal Cancer Targeted Drug Delivery and MR Imaging: Current Situation and Perspectives
Current Cancer Drug Targets Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Current Computational Approaches Towards the Rational Design of New Insecticidal Agents
Current Computer-Aided Drug Design Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Development and Characterization of Biodegradable Polymeric Microspheres of Metformin Hydrochloride
Nanoscience & Nanotechnology-Asia Damnacanthal: A Promising Compound as a Medicinal Anthraquinone
Anti-Cancer Agents in Medicinal Chemistry The Pictet-Spengler Reaction Still on Stage
Current Pharmaceutical Design Editorial Review 2015
Current Radiopharmaceuticals